

Evonik Financials & ESG KPIs

Financial KPIs Group	P. 2
ESG KPIs	P.3
Segment KPIs	P. 4-6
Group Income Statement	P. 7-8
Group Balance Sheet	P. 9
Group Cash Flow Statement	P. 10
Group Net Financial Position	P. 11
Definitions	P. 12

As of Q4 / FY 2025 (published March 4, 2026)

Evonik Group Financials

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
External Sales	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777	3,499	3,391	3,403	14,069
<i>Growth (%)</i>	23%	24%	-17%	-5%	1%	2%	0%	-1%	-1%	-11%	-12%	-5%	-7%
<i>Volumes (%)</i>	11%	-4%	-8%	4%	5%	5%	4%	4%	2%	-4%	-6%	2%	-2%
<i>Prices (%)</i>	12%	18%	-3%	-5%	-2%	0%	-2%	-2%	-2%	-1%	-1%	-2%	-1%
<i>Exchange Rates (%)</i>	-2%	5%	-2%	-1%	0%	-2%	0%	-1%	1%	-3%	-3%	-5%	-2%
<i>Other (incl. M&A; %)</i>	2%	5%	-4%	-3%	-2%	-1%	-2%	-2%	-2%	-3%	-2%	0%	-2%
Adjusted EBITDA	2,383	2,490	1,656	522	578	577	388	2,065	560	509	448	357	1,874
<i>Margin (%)</i>	15.9%	13.5%	10.8%	13.8%	14.7%	15.1%	10.8%	13.6%	14.8%	14.5%	13.2%	10.5%	13.3%
EBIT	1,173	942	-243	252	93	322	-91	577	299	236	-25	68	578
Adjusted EBIT	1,338	1,350	521	266	329	322	111	1,027	309	250	197	105	861
<i>Margin (%)</i>	8.9%	7.3%	3.4%	7.0%	8.4%	8.4%	3.1%	6.8%	8.2%	7.1%	5.8%	3.1%	6.1%
Adjusted EPS	2.12	2.26	0.79	0.42	0.50	0.58	0.16	1.67	0.59	0.34	0.27	0.15	1.36
Free Cash Flow	950	785	801	127	217	357	172	873	195	-211	300	411	695
Cash Conversion Rate ¹	40%	32%	48%					42%					37%
Capex (Cash outflow for investment in intan)	865	865	793	251	143	180	266	840	190	176	181	201	748
Capital employed (annual average)	14,799	16,192	15,406					14,493					14,038
ROCE (%)	9.0%	8.3%	3.4%					7.1%					6.1%
Dividend (€)	1.17	1.17	1.17					1.17					1.00
Employees (continuing operations)	33,004	34,029	33,409	33,090	32,757	32,040	31,930	31,930	31,585	31,273	31,297	31,053	31,053

¹ Free cash flow conversion = FCF / adj. EBITDA

Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published separately on our IR website: evonik.finance/investor-relations

	2021 FY	2022 FY	2023 FY	2024 FY	2025 FY
Strategy & Growth					
Sales share with "Next Generation Solutions"	41%	43%	43%	45%	48%
Governance & Compliance					
Training rate fighting money laundering	96%	97%	98%	99%	100%
Training rate antitrust law	83%	85%	89%	90%	91%
Training rate fighting corruption	92%	91%	86%	95%	96%
Training rate code of conduct	89%	89%	92%	96%	97%
Training rate Human Rights (new in 2024)			90%	84%	94%
Training rate Data security (new in 2025)					98%
Value Chain & Products					
Procurement volume (in € billion)	10.4	13.6	11.3	10.5	9.8
Production output (million metric tons)	9.5	8.4	7.5	7.3	6.0
Use of renewable raw materials in production	9.7%	11.1%	12.0%	9.0%	10.0%
Raw material suppliers (with >€100T annual procurement volume) covered by TfS assessments	69%	66%	67%	87%	86%
No. of sustainability audits (Evonik/TfS)	284	378	492	596	605
No. of sustainability assessments (Evonik/TfS)	1,345	1,545	1,296	1,309	926
R&D expenses (€ million)	464	461	443	459	418
The environment					
Scope 1 greenhouse gas emissions (million metric tons CO ₂)	4.38 ^a	4.22 ^a	3.89 ^b	3.39	2.99
Scope 2 greenhouse gas emissions (million metric tons CO ₂)	1.92 ^a	1.76 ^a	1.40 ^b	1.52	1.36
Scope 3 greenhouse gas emissions (million metric tons CO ₂)	23.4	20.5 ^a	18.9 ^b	21.6	19.5
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO ₂) vs base year	-43	-5 ^c	-15 ^c	-20	-31
Total water intake (in million m ³)	462 ^d	444 ^d	403	430	427
Specific water intake (in m ³ freshwater / metric ton production)	26.8 ^d	29.5 ^d	29.9	32.3	36.7
Production waste (thousand metric tons)	342 ^d	335 ^d	287	305	272
Specific production waste (in ton of waster per metric ton production)	0.036	0.04	0.038	0.042	0.045
Employees					
Early employee turnover	2.2%	1.9%	2.2%	1.7%	5.3%
Continuing professional development per employee (hours) ^b	5	4	4	1.7	2.1
Women at level "Executives" (circle 1)	18%	20%	22%	22%	21%
Women at level "Senior management" (circle 2)	18%	17%	19%	19%	22%
Women in management (circle 3)	29%	30%	30%	31%	32%
Women in management (circles 1-3)	28%	29%	30%	31%	32%
Safety					
Occupational health performance index	5.6	5.5	5.5	5.5	5.6
Accident frequency rate (no. of accidents / working hours) ^b	0.19	0.25	0.21	0.14	0.18
Incident frequency rate (no. of accidents / working hours) ^b	0.48	0.49	0.43	0.44	0.44

a: adjusted figures corresponding to GHG Protocol Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close process
 (for ESG KPI definitions please see separate "Definitions" page at the end of the file)

Advanced Technologies

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Sales	5,827	7,092	5,983	1,517	1,533	1,535	1,504	6,089	1,601	1,511	1,445	1,415	5,973
Growth (% yoy)	17%	22%	-16%	-3%	2%	2%	6%	2%	6%	-1%	-6%	-6%	-2%
Volumes (%)	11%	-3%	-8%	1%	2%	2%	4%	2%	6%	1%	-2%	2%	2%
Prices (%)	8%	20%	-4%	-4%	-1%	3%	1%	0%	-3%	-1%	-1%	-3%	-2%
Exchange Rates (%)	-2%	5%	-4%	-1%	0%	-3%	0%	-1%	1%	-4%	-3%	-5%	-3%
Other (incl. M&A; %)	0%	0%	0%	1%	1%	0%	1%	1%	2%	3%	0%	0%	1%
Sales Organics	1,681	1,868	1,742	409	441	408	408	1,664	426	401	411	395	1,634
Volumes (%)	+	-	-	=	+	=	+	+	+	-	+	+	+
Prices (%)	+	+	=	-	-	-	-	-	-	=	-	-	-
Sales Inorganics	2,357	3,031	2,491	625	641	615	607	2,490	621	614	595	566	2,395
Volumes (%)	+	=	-	=	+	+	=	+	=	-	-	=	=
Prices (%)	+	+	=	-	-	=	=	-	=	=	=	-	=
Sales Animal Nutrition	1,789	2,193	1,750	483	451	512	489	1,935	554	496	439	454	1,944
Volumes (%)	+	-	=	+	-	+	+	=	+	+	-	=	+
Prices (%)	+	+	-	+	+	+	+	+	-	-	-	-	-
Adjusted EBITDA	1,233	1,207	752	275	267	296	185	1,023	291	266	202	186	944
Margin (%)	21.2%	17.0%	12.6%	18.1%	17.4%	19.3%	12.3%	16.8%	18.2%	17.6%	14.0%	13.1%	15.8%
EBITDA yoy Organics	+	=	-	-	+	-	-	-	+	-	-	-	-
EBITDA yoy Inorganics	+	+	-	+	+	+	-	+	-	=	-	+	-
EBITDA yoy Animal Nutrition	+	-	-	+	+	+	+	+	+	+	-	-	-
EBIT				158	157	205	-3	517	183	137	65	60	445
Adjusted EBIT				159	157	186	62	565	181	150	89	71	492
Capital expenditures				80	66	77	143	367	56	82	72	132	342
Approx. Operating FCF				105	139	146	124	513	156	85	182	250	673
Capital employed (annual average)								7,018					6,907
ROCE (%)								8.1%					7.1%
Employees				-	9,669	9,647	9,568	9,568	-	9,312	9,189	9,177	9,177

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

Custom Solutions

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Sales	5,357	6,568	5,608	1,392	1,472	1,465	1,408	5,737	1,427	1,367	1,340	1,359	5,492
Growth (% yoy)	19%	23%	-15%	-3%	3%	4%	3%	2%	3%	-7%	-9%	-3%	-4%
Volumes (%)	14%	-3%	-11%	3%	8%	6%	5%	5%	2%	-5%	-8%	0%	-3%
Prices (%)	5%	13%	1%	-5%	-3%	0%	-2%	-2%	0%	1%	1%	1%	1%
Exchange Rates (%)	-1%	5%	-3%	-1%	-1%	-2%	0%	-1%	1%	-3%	-3%	-5%	-3%
Other (incl. M&A; %)	1%	8%	-2%	0%	-1%	0%	0%	0%	0%	0%	1%	1%	1%
Sales Additives	3,588	4,523	3,747	975	1,017	980	935	3,908	974	942	899	869	3,683
Volumes (%)	+	-	-	+	+	+	+	+	=	-	-	-	-
Prices (%)	+	+	=	-	-	=	=	-	=	=	=	=	=
Sales Care	1,768	2,045	1,861	417	455	485	473	1,829	453	425	441	491	1,809
Volumes (%)	+	=	-	-	=	+	=	=	+	-	-	+	=
Prices (%)	+	+	+	=	=	=	-	=	-	=	+	+	=
Adjusted EBITDA	1,086	1,162	852	231	281	287	179	978	256	254	215	184	909
Margin (%)	20.3%	17.7%	15.2%	16.6%	19.1%	19.6%	12.7%	17.0%	17.9%	18.6%	16.0%	13.5%	16.6%
EBITDA yoy Additives	+	+	-	+	+	+	+	+	+	-	-	=	-
EBITDA yoy Care	+	+	-	+	+	-	-	-	+	-	-	+	+
EBIT				155	205	223	-25	558	170	189	120	74	553
Adjusted EBIT				156	205	210	92	663	181	180	140	104	602
Capital expenditures				49	59	71	132	311	50	78	72	100	300
Approx. Operating FCF				86	146	172	196	600	44	112	172	314	642
Capital employed (annual average)								6,192					6,054
ROCE (%)								10.7%					9.9%
Employees				-	9,786	9,786	9,736	9,736	-	9,649	9,644	9,529	9,529

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

Infrastructure (incl. C4 business) / Other

in € million	2021 FY	2022 FY	2023 FY	2024 Q1 ¹	2024 Q2 ¹	2024 Q3 ¹	2024 Q4 ¹	2024 FY ¹	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Sales Infrastructure & Other	3,771	4,827	3,675	887	925	832	687	3,331	749	621	606	629	2,604
<i>Sales Infrastructure</i>				832	857	771	685	3,146	708	584	574	583	2,449
<i>Sales Other</i>				55	68	61	2	185	41	37	32	46	155
Adjusted EBITDA Infrastructure & Other	96	124	54	16	30	-6	24	64	13	-11	31	-13	21
<i>Adj. EBITDA Infrastructure</i>				66	108	68	33	275	61	38	54	59	213
<i>Adj. EBITDA Other</i>				-50	-78	-74	-9	-211	-48	-49	-23	-72	-192
EBIT	-316	-641	-611	-59	-268	-107	-63	-498	-54	-90	-210	-66	-420
Adjusted EBIT	-228	-224	-296	-49	-33	-74	-43	-201	-53	-80	-32	-67	-233
Capital expenditures	292	241	189	28	23	32	56	138	27	25	29	50	130
Employees	16,116	16,504	16,184	12,319	13,302	12,607	12,626	12,626	12,372	12,312	12,464	12,347	12,347

¹ Restated to reflect split of Technology & Infrastructure division into cross-site technology and site-specific infrastructure activities; smaller production sites, which often only serve one business line, have been allocated directly to the respective chemicals divisions

Group Income Statement

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Sales	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777	3,499	3,391	3,403	14,069
Cost of sales	-10,925	-14,257	-12,567	-2,795	-2,885	-2,804	-2,935	-11,419	-2,769	-2,568	-2,775	-2,714	-10,825
Gross profit on sales	4,030	4,231	2,700	1,001	1,045	1,028	664	3,738	1,008	931	616	689	3,244
Selling expenses	-1,717	-2,035	-1,836	-473	-473	-468	-479	-1,894	-454	-434	-420	-428	-1,736
Research and development expenses	-464	-460	-443	-111	-109	-106	-133	-459	-106	-105	-104	-102	-418
General administrative expenses	-546	-554	-488	-129	-353	-128	-129	-740	-126	-125	-111	-113	-474
Other operating income & expenses	-138	-252	-186	-38	-22	-7	-24	-89	-25	-33	-7	13	-52
Result from investments recognized at equity	8	12	10	2	5	3	10	21	2	2	1	9	14
Income before financial result and income taxes, cont. ops. = EBIT	1,173	942	-243	252	93	322	-91	577	299	236	-25	68	578
Financial Result	-88	-19	-108	-33	-31	-48	-30	-143	-29	-44	-52	-30	-156
Income before income taxes, continuing operations	1,085	923	-351	219	62	274	-121	434	270	192	-77	38	422
Income taxes	-316	-369	-101	-59	-61	-47	-28	-194	-34	-68	-25	-18	-145
Income after taxes, continuing operations	769	554	-452	160	1	227	-149	240	236	124	-102	20	277
Income after taxes, discontinued operations	-2	1	-	0	0	0	1	0	0	0	0	0	0
Income after taxes	767	555	-452	160	1	227	-148	240	236	124	-102	20	277
thereof attributable to non-controlling interests	21	15	13	4	6	4	4	18	3	4	4	2	12
Shareholders of EVONIK Industries AG (net income)	746	540	-465	156	-5	223	-152	222	233	120	-106	18	265
EPS	1.60	1.16	-1.00	0.33	-0.01	0.48	-0.32	0.48	0.50	0.26	-0.23	0.04	0.57

Group Adjusted Income Statement

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Sales	14,955	18,488	15,267	3,796	3,930	3,832	3,599	15,157	3,777	3,499	3,391	3,403	14,069
Adjusted EBITDA	2,383	2,490	1,656	522	578	577	388	2,065	560	509	448	357	1,874
Adjusted depreciation and amortization	-1,045	-1,140	-1,135	-256	-249	-255	-277	-1,038	-251	-259	-251	-252	-1,013
Adjusted EBIT	1,338	1,350	521	266	329	322	111	1,027	309	250	197	105	861
Adjusted net financial result	-97	-19	-103	-33	-31	-48	-31	-143	-29	-44	-52	-37	-162
Adjusted depreciation and amortization on intar	162	169	153	35	35	34	39	144	34	32	33	32	131
Adjusted income before income taxes, cont.	1,403	1,500	571	268	333	308	119	1,028	314	238	178	100	830
Adjusted income taxes, continuing operations	-396	-431	-188	-67	-93	-33	-41	-233	-36	-74	-46	-28	-184
Adjusted income after taxes	1,007	1,069	383	201	240	275	78	795	278	164	132	72	646
Adjusted non-controlling interest	-21	-15	-13	-4	-6	-4	-4	-18	-3	-4	-4	-1	-12
Adjusted net income	986	1,054	370	197	234	271	74	777	275	160	128	71	634
Adjusted EPS	2.12	2.26	0.79	0.42	0.50	0.58	0.16	1.67	0.59	0.34	0.27	0.15	1.36

Adjustments

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Restructuring measures	-32	-121	-64	-2	-228	-2	-173	-405	-12	7	-31	-6	-42
Acquisitions and divestments	-29	40	-237	-11	-2	-18	-3	-34	-11	4	0	-7	-14
Other special items	-104	-327	-463	-1	-6	20	-24	-11	13	-25	-191	-24	-227
= Adjustments	-165	-408	-764	-14	-236	0	-200	-450	-10	-14	-222	-37	-283

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

Group Balance Sheet
Assets

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY
Intangible assets	6,045	5,710	5,525	5,556	5,552	5,417	5,571	5,426	5,176	5,131	5,097
Property, plant and equipment	6,963	6,962	6,294	6,320	6,307	6,270	6,450	6,305	6,127	5,933	6,006
Right of use assets (capitalized leasing)	608	972	965	940	928	903	947	905	867	893	892
Investments recognized at equity	81	88	52	44	40	43	49	51	45	45	45
Trade accounts receivable									67	54	1
Financial assets	581	441	460	445	444	509	467	424	455	418	419
Deferred tax assets	1,755	890	642	672	678	677	664	629	624	659	436
Other income tax assets	16	19	20	21	22	21	25	24	22	22	22
Other non-financial assets	125	64	78	77	58	59	69	110	71	87	96
Non-current assets	16,174	15,146	14,036	14,075	14,029	13,899	14,242	13,874	13,454	13,242	13,014
Inventories	2,548	2,820	2,349		2,599	2,658	2,662	2,751	2,649	2,555	2,300
Other income tax assets	199	98	209	189	179	122	166	138	103	86	94
Trade accounts receivable	1,954	1,898	1,607		1,813	1,706	1,622	1,732	1,625	1,581	1,525
Other non-financial assets	382	517	373	407	462	433	381	440	377	363	333
Financial assets	571	610	381	371	342	284	216	574	467	266	220
Cash and cash equivalents	456	645	749	794	521	460	461	733	379	454	495
Current assets	6,110	6,588	5,668	6,109	5,916	5,663	5,508	6,368	5,600	5,305	4,967
Assets held for sale	0	76	236	264	261	0	0	0	0	0	0
Current assets	6,110	6,664	5,904	6,373	6,177	5,663	5,508	6,368	5,600	5,305	4,967
Total assets	22,284	21,810	19,940	20,448	20,206	19,562	19,750	20,242	19,054	18,547	17,981

Liabilities

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY
Issued capital	466	466	466	466	466	466	466	466	466	466	466
Reserves	8,823	10,508	8,444	8,672	8,401	8,552	8,554	8,719	8,028	7,883	7,644
Equity attributable to shareholders of Evonik Industries AG	9,289	10,974	8,910	9,138	8,867	9,018	9,020	9,185	8,494	8,349	8,110
Equity attributable to non-controlling interests	83	82	76	78	71	77	80	82	65	64	64
Total equity	9,372	11,056	8,986	9,216	8,938	9,095	9,100	9,267	8,559	8,413	8,174
Provisions for pensions and other post-employment benefits	3,766	1,359	1,858	1,828	1,575	1,564	1,662	1,449	1,383	1,387	1,490
Other provisions	657	542	517	520	688	681	734	734	651	667	591
Deferred tax liabilities	628	661	608	613	630	614	638	633	625	629	576
Other income tax liabilities	195	246	268	273	271	266	254	258	268	246	228
Financial liabilities	3,531	4,117	3,502	3,519	3,485	3,135	3,162	3,629	3,586	3,663	3,476
Other payables	143	182	153	139	129	130	141	97	109	95	118
Non-current liabilities	8,920	7,107	6,906	6,892	6,778	6,390	6,591	6,800	6,622	6,687	6,479
Other provisions	892	732	606	681	711	833	923	955	695	724	787
Other income tax liabilities	211	189	124	152	151	111	87	86	63	59	58
Financial liabilities	477	429	1,153	1,130	1,205	1,083	1,034	941	1,215	830	689
Trade accounts payable	2,022	1,735	1,521	1,675	1,682	1,511	1,600	1,702	1,440	1,359	1,401
Other payables	390	501	457	485	535	539	415	491	460	475	393
Current liabilities	3,992	3,586	3,861	4,123	4,284	4,077	4,059	4,175	3,873	3,447	3,328
Liabilities associated with assets held for sale	0	61	187	217	206	0	0	0	0	0	0
Current liabilities	3,992	3,647	4,048	4,340	4,490	4,077	4,059	4,175	3,873	3,447	3,328
Total equity and liabilities	22,284	21,810	19,940	20,448	20,206	19,562	19,750	20,242	19,054	18,547	17,981

Group Cash Flow Statement

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2025 FY
Income before financial result and income taxes, continuing operations = EBIT	1,173	942	-243	252	93	321	-90	577	299	236	-25	68	578
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	1,073	1,568	1,841	265	250	234	368	1,117	240	260	428	275	1,203
Result from investments recognized at equity	-8	-12	-10	-2	-6	-3	-10	-21	-2	-3	0	-9	-14
Gains/losses on disposal of non current assets	43	-50	-1	-3	-1	21	5	22	15	4	5	-13	11
Change in inventories	-675	-270	310	-218	-34	-99	54	-297	-140	7	94	259	220
Change in trade accounts receivable	-449	42	105	-180	-35	118	118	21	-143	-16	52	112	5
Change in trade accounts payable and current advance payments received from customers	680	-257	-157	-11	-11	-180	4	74	185	-228	-67	-32	-142
Change in provisions for pensions and other post-employment benefits	83	-19	-55	-31	-13	0	-4	-48	-4	-13	-28	-4	-49
Change in other provisions	207	-149	-141	76	192	126	141	535	37	-341	40	10	-254
Change in miscellaneous assets/liabilities	-23	10	152	-28	-23	16	-45	-81	-100	78	7	-6	-21
Cash inflows from dividends	19	19	25	-	20	1	6	27	0	19	0	7	26
Tax payments relating to carve-out of the methacrylates business	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-308	-174	-232	-14	-72	-18	-109	-213	-2	-38	-25	-55	-120
Cash flow from operating activities, continuing operations	1,815	1,650	1,594	378	360	537	438	1,713	385	-35	481	612	1,443
Cash flow from operating activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash flow from operating activities	1,815	1,650	1,594	378	360	537	438	1,713	385	-35	481	612	1,443
Cash outflows for investments in intangible assets, property, plant and equipment, investments	-865	-865	-793	-251	-143	-180	-266	-840	-190	-176	-181	-201	-748
Cash outflows for investments in shareholdings	-85	-27	-76	-3	-4	-14	0	-15	0	0	-1	0	0
Cash outflows for loss from divestments of shareholdings	-145	97	-32	-13	0	0	0	-13	0	-1	0	0	-2
Cash outflows from divestments of businesses and other shareholdings	-21	-	-5	-	0	0	0	-6	0	0	0	0	0
Cash inflows from divestments of intangible assets, property, plant and equipment, investments	9	5	15	16	3	-5	7	21	8	0	1	12	21
Cash inflows for loss from divestments of shareholdings	2	-	43	-	3	17	-4	16	3	6	0	9	18
Cash inflows for investments in shareholdings	-	-	2	-	-	0	0	0	2	1	0	10	13
Cash inflows/outflows relating to securities, deposits and loans	23	-3	161	-13	14	85	52	137	-352	199	164	-4	8
Cash inflows from interest	12	16	32	12	8	11	6	37	20	7	6	5	38
Cash flow from investing activities, continuing operations	-1,070	-777	-653	-252	-119	-86	-205	-663	-509	36	-11	-169	-652
Cash flow from investing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash flow from investing activities	-1,070	-777	-653	-252	-119	-86	-205	-663	-509	36	-11	-169	-652
Cash inflows/outflows relating to capital contributions	0	0	0	0	0	0	0	0	1	3	0	0	4
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-545	-545	0	-545	0	0	-545	-	-545	0	0	-545
Cash outflows for dividends to non-controlling interests	-21	-13	-10	-4	-12	0	-4	-20	-1	-4	-4	-1	-10
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	-5	-	-	0	0	0	0	0	-19	0	0	-19
Cash outflows for the purchase of treasury shares	-15	-16	-16	-12	0	0	0	-12	0	-1	0	0	-1
Cash inflows from the sale of treasury shares	12	12	12	-	9	0	0	9	0	1	0	0	1
Cash inflows from the addition of financial liabilities	655	1,649	716	19	134	487	68	708	521	308	921	97	1,833
Cash outflows for repayment of financial liabilities	-948	-1,577	-893	-82	-65	-946	-261	-1,354	-107	-79	-1,252	-485	-1,909
Cash inflows/outflows in connection with financial transactions	91	-104	12	11	-16	7	-8	-7	0	5	0	11	16
Cash outflows for interest	-94	-73	-99	-17	-15	-52	-25	-109	-14	-12	-53	-22	-101
Cash flow from financing activities, continuing operations	-856	-672	-823	-85	-510	-504	-230	-1,330	400	-343	-388	-400	-731
Cash flow from financing activities, discontinued operations	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash flow from financing activities	-856	-672	-823	-85	-510	-504	-230	-1,330	400	-343	-388	-400	-731
Change in cash and cash equivalents	-111	201	118	41	-269	-53	3	-280	276	-342	82	43	60
Cash and cash equivalents as of beginning of period	563	456	645	749	794	519	460	749	460	735	379	454	461
Change in cash and cash equivalents	-111	201	118	41	-269	-53	3	-280	276	-342	82	43	60
Changes in exchange rates and other changes in cash and cash equivalents	4	-12	-14	4	-4	-7	-2	-8	-3	-14	-7	-2	-26
Cash and cash equivalents as of end of period	456	645	749	794	521	459	461	461	733	379	454	495	495
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash and cash equivalents as on the balance sheet as of end of period	456	645	749	794	521	459	461	461	733	379	454	495	495

Group Net Financial Position

in € million	2021 FY	2022 FY	2023 FY	2024 Q1	2024 Q2	2024 Q3	2024 FY	2025 Q1	2025 Q2	2025 Q3	2025 FY
Non-current financial liabilities	-3,527	-4,074	-3,320	-3,302	-3,288	-2,955	-2,961	-3,429	-3,393	-3,482	-3,314
Current financial liabilities	-232	-243	-1,006	-979	-1,105	-971	-883	-845	-1,136	-771	-617
Financial debt	-3,759	-4,317	-4,326	-4,281	-4,393	-3,926	-3,844	-4,274	-4,529	-4,253	-3,931
- Cash and cash equivalents	456	645	749	794	521	460	461	733	379	454	495
- Current securities	446	413	261	269	259	176	128	482	285	121	124
- Other financial assets	0	2	6	6	2	4	2	1	1	1	1
Financial assets	902	1,060	1,016	1,069	782	640	591	1,216	665	576	620
Net financial debt/cash as stated on the balance sheet	-2,857	-3,257	-3,310	-3,212	-3,611	-3,286	-3,253	-3,058	-3,864	-3,677	-3,311
Net financial debt/cash, discontinued operations	-	-	-	-	0	0	0	0	0	0	0
Net financial debt/cash including discontinued operations	-2,857	-3,257	-3,310	-3,212	-3,611	-3,286	-3,253	-3,058	-3,864	-3,677	-3,311

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TFS Assessments	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
Specific water intake <small>in m³ freshwater per metric ton production</small>	Freshwater usage in relation to production.
Total water intake	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).